A few weeks after the first occurrence of the previously unknown corona virus (nCoV-2019), BioCopy held its 2nd Investors’ Symposium in Zurich on 23 January 2020. Around 50 interested parties and shareholders gathered in the traditional premises of Villa Escher for this event. Dr. Günter Roth (CEO BioCopy GmbH), Dr. Thomas Langer (Board BioCopy Holding AG) and the new board members Professor Alexander von Gabain, Pascal Brenneisen and Rainer Boehm reported on the current status and projected activities of the company. The interested audience, consisting of investors, potential investors and cooperation partners, had the opportunity to gain up-to-date insights. In particular, the acquisition of Biametrics was considered a very positive success.
The new members of the Board of Directors are:
Professor Alexander von Gabain is the founder of several biotech companies, including Intercell AG, which registered and launched a novel vaccine against Japanese Encephalitis worldwide.
Rainer Boehm held senior management positions from 1988 to 2017, including as Chief Commercial & Medical Affairs Officer (2014-2016) and interim CEO of Novartis Pharma AG (2016).
Pascal Brenneisen has proven international expertise and networks in pharmaceuticals, strategic business development, marketing and sales. He held several positions at pharmaceutical companies such as Novartis (President of Novartis Switzerland) and Sandoz (CEO UK & Ireland).